Status:
COMPLETED
Finistere Myeloma Observatory (OMYFIN)
Lead Sponsor:
University Hospital, Brest
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Current molecular risk stratification of multiple myeloma (MM), based on the presence of t(4 ;14) and 17p deletion, cannot fully explain treatment outcome heterogeneity, as other features also predict...
Detailed Description
This single-center retrospective study, is designed to enroll all consecutive newly diagnosed adult patients aged ≥18 years, transplant-eligible and not. All patients are routinely tested for CKS1B an...
Eligibility Criteria
Inclusion
- Age at or over 18 years
- Symptomatic multiple myeloma
- Informed consent given
- FISH-based cytogenetic results obtained
Exclusion
- Age under 18 years
- MGUS or SMM
- No informed consent
- No FISH-based cytogenetic results
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06552221
Start Date
January 1 2012
End Date
June 30 2023
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29200